SAN DIEGO, March 10, 2003 (PRIMEZONE) -- Stellar International Inc. (TSX Venture Exchange:YYS) (OTCBB:SLRXF), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today reported that Peter Riehl was recently featured in an interview by SmallCapVoice.com. The interview covers all of the latest news for Stellar and features Mr. Riehl's personal insights into the company's formation and growth to date. The Web cast is online at http://64.176.182.15/slrxf/slrxf.html.
"We are pleased to be featured on SmallCapVoice.com and always welcome the opportunity to share our views with the investment community," said Mr. Riehl.
SmallCapVoice.com's Founder and CEO Stuart Smith said, "We're thrilled to be working with Stellar and learning about their current level of success. We look forward to hearing more exciting news from them in the near future. Our goal is to reach out to the existing shareholder base while providing an entirely new audience to this exciting company and its story."
Stellar International has developed and is marketing three products in Canada based on its core polysaccharide technology: NeoVisc(R), for the treatment of osteoarthritis, Uracyst(R)-S and the Uracyst Test Kit, Stellar's patented technology for the diagnosis and treatment of Interstitial Cystitis (IC), an inflammatory disease of the urinary bladder wall. The Uracyst treatment for IC costs less than competing products and has shown a good symptomatic response rate.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
The Private Securities Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this Press Release (as well as information included in oral statements or other written statements made or to be made) contains statements that are forward-looking, such as those relating to consummation of transactions, anticipated future revenues and/or success of current product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ materially from those expressed in any forward-looking statements.